Anteris Technologies (AVR.AX) Stock Analysis & Winston Score

Anteris Technologies is an Australian medical device company that develops artificial heart valves. Its main product is the DurAVR transcatheter heart valve, which is designed to replace damaged aortic valves in patients without open-heart surgery. The company sells to hospitals and cardiac surgeons, competing in the fast-growing transcatheter aortic valve replacement (TAVR) market. Anteris makes money by selling its heart valve devices to medical centers, though it is still in the clinical trial and early commercialization stage and is not yet profitable. It operates primarily in Australia, Europe, and the United States, where it is running trials to gain regulatory approval. The company's key competitive claim is that DurAVR uses a single-piece, naturally shaped valve design that may outperform older multi-piece designs — but the central risk is that it must first win full regulatory clearance in major markets, particularly the U.S., before it can generate meaningful revenue.